Grosse Chance WKN 931506
Seite 13 von 14 Neuester Beitrag: 02.05.10 14:39 | ||||
| Eröffnet am: | 04.04.07 09:33 | von: plusquamperf. | Anzahl Beiträge: | 342 |
| Neuester Beitrag: | 02.05.10 14:39 | von: _bbb_ | Leser gesamt: | 32.203 |
| Forum: | Hot-Stocks | Leser heute: | 5 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 8 | 9 | 10 | 11 | 12 | | 14 > | ||||
Das ist nur meine persönliche Meinung.
Gruss
wenn die Zahlen eingepreist waren, dann frage ich mich, warum an dem Tag
das Handelsvolumen so riesengroß war??
Die tage, Wochen, Monate zuvor konnte man das aber nicht beobachten.
Ich meine fast zu behaupten, dass sich der Kurs bei geringeren Handelsumsätzen eher hoch rangelt, wie bei
größeren Handelsumsaätzen.
Ich versteh es auch nicht so recht... BUT WE WILL SEE!
Ich bin aber echt gespannt, wenn beim nächsten Mal die Zahlen presäntiert werden,
ob da der kurs anzieht?
MfG
Ne,das mach ich nicht,ich distanziere mich von den Darstellungen der User im Board.
Gruss
SK-USA 29.05.08 = 0,300$
aktueller Wechselkurs €/$ = 1,549
...dies entspricht einem Tax-Kurs für GTEC = 0,194€
realer Tax-Kurs FRANKFURT = 0,172€ ----- ASK FRANKFURT = 0,190€ (unter Pari !!!)
>>> es müssen Informationen der "lahmen" PR-Abteilung her !
ax
Genesis Pharmaceuticals Closes $30 Million Private Note Placement
LAIYANG, China, June 3 /Xinhua-PRNewswire-FirstCall/ --
Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GTEC) (''Genesis'' or the ''Company''), a leading pharmaceutical company in the People's Republic of China, today announced that on May 30, 2008, it successfully completed a private placement of an aggregate principal amount of $30,000,000 of its three year convertible notes (the ''Notes'').
The Notes carry an annual interest rate of 6.0% and are convertible into shares of the Company's Common Stock at a conversion price of $0.20 per share. In connection with the private placement of the Notes, the Company issued to purchasers of the Notes an aggregate of 75,000,000 five-year warrants to purchase shares of its Common Stock at an exercise price of $0.25 per share. The lead investor in the private placement was Pope Investments, LLC.
Genesis intends to use a significant portion of the net proceeds from this private placement to pay for the rights to manufacture and distribute a new Chinese Class I drug, Ligustrazine Ferulic Acid Acetate (''LFAA''), and for the marketing expenses associated with the launch of LFAA. LFAA is a cardiac cerebral vascular medicine that helps to reduce blood clotting and prevent blood platelets from clumping together. The Company expects to receive approval of LFAA from China's State Food and Drug Administration in the first half of calendar year 2009 and to start generating revenue from sales of this drug in the latter half of calendar year 2009. The Company projects that revenue from LFAA sales in Genesis' fiscal year 2010 (July 2009 through June 2010) will be over $23 million, and that revenues from LFAA sales will be over $35 million in fiscal year 2011, and to continue to grow thereafter. The Company estimates that the profit margin on LFAA sales will be above 80%.
The Company also intends to use a significant portion of the net proceeds from the private placement to purchase manufacturing equipment and upgrade the Company's facilities.
''We believe that this financing provides Genesis with new capital with which to pay the balance of what it costs to acquire and market LFAA, a drug that we believe has the potential to significantly enhance our future growth and profitability,'' said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. ''We are investing in our future growth and development while working to increase Company value for our shareholders.''
According to a make good arrangement entered into in connection with the private placement of the Notes, Mr Cao Wubo agreed to put 150,000,000 shares of his common stock into escrow. 60,000,000 of those shares will be transferred to the private placement investors in the event that either the Company's 2008 earnings before taxes are less than $26.7 million and/or the Company's fully diluted earnings per share are less than $0.04 and 90,000,000 of such shares will be transferred to the private placement investors in the event that the Company's 2009 earnings before taxes are less than $38.4 million and/or the Company's fully diluted earnings per share are less than $0.058 (or $0.056 if the 20,000,000 shares of common stock held in escrow in connection with the Company's November private placement have been released from escrow).
Neither the Notes, the warrants nor the shares of common stock issuable upon conversion of the Notes and the exercise of the warrants issued in this private placement have been registered under the Securities Act of 1933, as amended, and may not be offered or sold by the investors in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Genesis Pharmaceuticals Enterprises, Inc. has agreed to file a registration statement covering the resale by the investors of the shares of common stock issuable upon conversion of the Notes and exercise of the warrants issued in this private placement within 45 days of the closing date of the private placement. For more detailed information on this financing, please refer to the Company's Form 8-K and related exhibits that will be filed with the Securities and Exchange Commission on Tuesday, June 3, 2008.
Brean, Murray, Carret & Co, served as the sole placement agent for this placement.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung CFO
Phone: +1-954-727-8436
Email: genesispharm@gmail.com
Web: http://www.genesis-china.net
CCG Elite Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgelite.com
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
8k ist draussen mit Finanzdealdetails ! http://www.sec.gov/Archives/edgar/data/1091164/...08-033398-index.htm
Wenn ein Groß-Investor einsteigt, erhält er natürlich als Gegenleistung Aktien-Optionen bzw. Aktien (mit einen gewissen Gegenwert), die er (wann auch immer) auslösen kann.
besagter "Aktien-Ami" DENKT natürlich, dieses auslösen macht der Groß-Investor sofort - dadurch kommen auf einen Schlag sehr, sehr viele Aktien auf den Markt, die den Preis drücken...
Genesis Pharmaceuticals Closes $30 Million Private Note Placement
LAIYANG, China, June 3 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GTEC) (“Genesis” or the “Company”), a leading pharmaceutical company in the People’s Republic of China, today announced that on May 30, 2008, it successfully completed a private placement of an aggregate principal amount of $30,000,000 of its three year convertible notes (the “Notes”).
The Notes carry an annual interest rate of 6.0% and are convertible into shares of the Company’s Common Stock at a conversion price of $0.20 per share. In connection with the private placement of the Notes, the Company issued to purchasers of the Notes an aggregate of 75,000,000 five-year warrants to purchase shares of its Common Stock at an exercise price of $0.25 per share. The lead investor in the private placement was Pope Investments, LLC.
Genesis intends to use a significant portion of the net proceeds from this private placement to pay for the rights to manufacture and distribute a new Chinese Class I drug, Ligustrazine Ferulic Acid Acetate (“LFAA”), and for the marketing expenses associated with the launch of LFAA. LFAA is a cardiac cerebral vascular medicine that helps to reduce blood clotting and prevent blood platelets from clumping together. The Company expects to receive approval of LFAA from China’s State Food and Drug Administration in the first half of calendar year 2009 and to start generating revenue from sales of this drug in the latter half of calendar year 2009. The Company projects that revenue from LFAA sales in Genesis’ fiscal year 2010 (July 2009 through June 2010) will be over $23 million, and that revenues from LFAA sales will be over $35 million in fiscal year 2011, and to continue to grow thereafter. The Company estimates that the profit margin on LFAA sales will be above 80%.
The Company also intends to use a significant portion of the net proceeds from the private placement to purchase manufacturing equipment and upgrade the Company’s facilities.
“We believe that this financing provides Genesis with new capital with which to pay the balance of what it costs to acquire and market LFAA, a drug that we believe has the potential to significantly enhance our future growth and profitability,” said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. “We are investing in our future growth and development while working to increase Company value for our shareholders.”
According to a make good arrangement entered into in connection with the private placement of the Notes, Mr Cao Wubo agreed to put 150,000,000 shares of his common stock into escrow. 60,000,000 of those shares will be transferred to the private placement investors in the event that either the Company’s 2008 earnings before taxes are less than $26.7 million and/or the Company’s fully diluted earnings per share are less than $0.04 and 90,000,000 of such shares will be transferred to the private placement investors in the event that the Company’s 2009 earnings before taxes are less than $38.4 million and/or the Company’s fully diluted earnings per share are less than $0.058 (or $0.056 if the 20,000,000 shares of common stock held in escrow in connection with the Company’s November private placement have been released from escrow).
Neither the Notes, the warrants nor the shares of common stock issuable upon conversion of the Notes and the exercise of the warrants issued in this private placement have been registered under the Securities Act of 1933, as amended, and may not be offered or sold by the investors in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Genesis Pharmaceuticals Enterprises, Inc. has agreed to file a registration statement covering the resale by the investors of the shares of common stock issuable upon conversion of the Notes and exercise of the warrants issued in this private placement within 45 days of the closing date of the private placement. For more detailed information on this financing, please refer to the Company’s Form 8-K and related exhibits that will be filed with the Securities and Exchange Commission on Tuesday, June 3, 2008.
Brean, Murray, Carret & Co, served as the sole placement agent for this placement.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People’s Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal-based medical drugs.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung CFO
Phone: +1-954-727-8436
Email: genesispharm@gmail.com
Web: http://www.genesis-china.net
CCG Elite Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgelite.com
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
-0- 06/03/2008
/CONTACT: Ms. Elsa Sung CFO of Genesis Pharmaceuticals Enterprises, Inc., +1-954-727-8436, or genesispharm@gmail.com; Mr. Crocker Coulson, President of CCG Elite Investor Relations, Inc.,
+1-646-213-1915, or crocker.coulson@ccgir.com, both for Genesis Pharmaceuticals Enterprises, Inc./
/Web site: http://www.genesis-china.net
http://www.ccgelite.com /
(GTEC)
By: China Bio Today Friday, June 06, 2008 7:55 PM
Sectors: China , Medical
Symbols: GTEC
Email Comments (0) Post Comment Bookmark It
Genesis Pharmaceuticals Enterprises, Inc. (OTCBB: GTEC) raised new capital through a private placement of $30 million in three-year convertible notes, which have an interest rate of 6% and are convertible into Genesis stock at $.20 per share. That last number represents an unusually large 31% discount, because at the time of the placement, Genesis was selling for $.29 per share. Looking at the financial report of Genesis, it is not clear why the company had to settle for such onerous terms to complete the financing.
When $30 million of notes is converted into stock at $.20 per share, Genesis will have an additional 150 million shares outstanding. Currently, there are 390.5 million shares. In addition, the newly issued notes include a five-year warrant allowing holders to buy another 75 million shares at a price of $.25 per share. In all, the new financing has the capability of increase the number of shares by 57% in return for $48.75 million.
As with the most recent financing, a $5 million note private placement completed in November 2007, the private placement was led by Pope Investments, LLC of Memphis, TN.
At the time of the $5 million financing – and again with this most recent capital raise – Genesis says that the proceeds will be used to buy the rights to Ligustrazine Ferulic Acid Acetate, an anti-clotting agent that qualifies as a China Class I drug. Class I designation signifies the drug has never been imported to China, nor has it been approved elsewhere in the world. Genesis expects the SFDA to approve LFAA in the first half of 2009. Revenues should begin toward the end of 2009. Genesis expects LFAA revenues in its fiscal year 2010 (July 2009 through June 2010) will surpass $23 million, and that they will top $35 million in fiscal year 2011. Gross margins for the product are predicted to be above 80%.
In addition to paying for the rights and underwriting the marketing expense, Genesis says the recent financing will but used to buy manufacturing equipment and upgrade its facilities.
The terms of the financing also contain a substantial “make good” clause. The Chairman and CEO of Genesis, Cao Wubo, put 150,000,000 shares of his common stock into escrow. 60,000,000 of those shares will be transferred to the private placement investors if Genesis’ 2008 earnings before taxes are less than $26.7 million and/or its fully diluted earnings per share are less than $0.04. Another 90,000,000 of the escrowed shares will be transferred if Genesis’ 2009 earnings before taxes are less than $38.4 million and/or its fully diluted earnings per share are less than $0.058. That number is dropped to $0.056 if the 20,000,000 shares of common stock from the November private placement are released from escrow.
After the company’s third quarter, completed March 31, 2008, Genesis reported that nine-month revenues grew by 28% to $71 million. Net income climbed 74% to $12.9 million. Before income taxes, the company recorded $19.7 in income and per share earnings of 5 cents, indicating that it stands a good chance of meeting its “make good” clause for 2008. The company said it had $21.6 million in cash and working capital of $30.6 million.
Given that the company has a solid financial footing and is nicely profitable, the terms of the Note financing, especially the large number of shares that are available to be converted, seem like the lenders struck a better deal than the company.
Genesis’ best selling products are the oral antibiotic Clarithromycin sustained-release tablets and Itopride Hydrochloride granules, an anti-constipation drug, and a new TCM product, the Baobaole chewable tablet, which is used to ease gastric discomfort.
After the financing was announced, the stock price of Genesis shares dropped 8 cents to $.21, close to the conversion price of the newly announced notes, and a decline of 28%.
Disclosure: none.
War Gtec überbewertet??
Versteh das mal einer.
Zum Glück bin ich nur mit einer kleinen Posi drin!
Wagt jemand eine Zukunftsprognose zu Ende 2008 ?
MfG.
--------------------------------------------------
12-Jun-2008
Change in Directors or Principal Officers, Financial St
Item 5.02. Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On June 9, 2008, the Board of Directors of Genesis Pharmaceuticals Enterprises, Inc. (the "Company") by unanimous written consent approved the hiring of Elsa Sung as the full-time Chief Financial Officer of the Company effective June 10, 2008.
Ms. Sung, age 34, has served as Chief Financial Officer of the Company since October 2007. Prior to June 2008, she was also Vice President of CFO Oncall, Inc. Prior to joining CFO Oncall, Inc., Ms. Sung was an Audit Manager at Sherb & Co., Boca Raton, Florida, responsible for managing, monitoring, as well as performing audits for domestic and international clients. Before joining Sherb & Co., Ms. Sung was a Senior Internal Auditor at Applica Consumer Products, Inc., a U.S. public traded company. Prior to this, Ms. Sung was with Ernst & Young, LLP in West Palm Beach, Florida as a Senior Auditor in the Assurance and Advisory Business Service Group. Ms. Sung is a licensed CPA in the State of Georgia and a member of the American Institute of Certified Public Accountants. She received her Master of Business Administration and Bachelor's Degree, graduated "Cum Laude", in Accounting from Florida Atlantic University. She also holds a Bachelor's Degree in Sociology from National Chengchi University in Taipei, Taiwan.
The Company and Ms. Sung executed an employment agreement effective as of June 10, 2008 (the "Employment Agreement"). In accordance with the terms of the Employment Agreement, Ms. Sung will receive an annual base salary of $120,000 and will be entitled to receive performance bonuses of (i) $18,000 if the Company is successfully listed or quoted on the New York Stock Exchange, the American Stock Exchange, the NASDAQ Select Market, the NASDAQ Global Market or the NASDAQ Capital Market; (ii) $8,000 if the Company meets its 2008 Guaranteed EBT; and (iii) $20,000 if the Company meets its 2009 Guaranteed EBT. In addition, Ms. Sung will be granted 300,000 options in accordance with the vesting and pricing schedule set forth in the Employment Agreement.
The foregoing description of the Employment Agreement is merely a summary, is not intended to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement. The Employment Agreement is filed as Exhibit 10.1 to this Form 8-K, and the full text of such exhibit is incorporated herein by reference.
Ms. Sung has no family relationships with any of the executive officers or directors of the Company. There have been no transactions in the past two years to which the Company or any of its subsidiaries was or is to be a party, in which Mr. Sung had, or will have, a direct or indirect material interest.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
10.1 Employment Agreement, effective as of June 10, 2008 by and between
Genesis Pharmaceuticals Enterprises, Inc. and Elsa Sung
Posten 5,02. Abfahrt of Directors oder bestimmte Officers; Wahl der Direktoren, die Bestellung bestimmter Officers; Ausgleichsvereinbarung bestimmter Officers.
Am 9. Juni 2008, das Board of Directors der Genesis Pharma Enterprises, Inc. (das "Unternehmen") durch einstimmigen schriftlichen Zustimmung genehmigt die Einstellung von Elsa Sung als die Vollzeit-Chief Financial Officer des Unternehmens wirksam 10. Juni 2008.
Frau Sung, Alter 34, diente als Chief Financial Officer des Unternehmens seit Oktober 2007. Vor Juni 2008, sie war auch Vice President des CFO Oncall, Inc. Vor seinem Eintritt bei CFO Oncall, Inc., Frau Sung wurde ein Audit Manager bei Sherb & Co., Boca Raton, Florida, verantwortlich für die Verwaltung, Überwachung, wie ebenso wie die Durchführung Audits für nationale und internationale Kunden. Vor seinem Wechsel zu Sherb & Co., Frau Sung war ein Senior Internal Auditor bei Applica Consumer Products, Inc., eine US-amerikanische Öffentlichkeit gehandelten Unternehmen. Davor war Frau Sung wurde mit Ernst & Young LLP in West Palm Beach, Florida als Senior Auditor bei der Assurance and Advisory Business Service Group. Frau Sung ist ein lizenzierter CPA im US-Bundesstaat Georgia und Mitglied des American Institute of Certified Public Accountants. Sie erhielt ihren Master of Business Administration und Bachelor-Abschluss, Diplom "cum laude", im Rechnungswesen aus Florida Atlantic University. Sie ist außerdem Inhaber eines Bachelor's Degree in Soziologie von National Chengchi University in Taipei, Taiwan.
Die Gesellschaft und Frau Sung ausgeführt einen Arbeitsvertrag Vereinbarung mit Wirkung zum 10. Juni 2008 (der "Beschäftigungs-Abkommen"). In Übereinstimmung mit den Bestimmungen des Abkommens Beschäftigung, Frau Sung erhalten ein jährliches Grundgehalt von 120000 $ und wird Anspruch auf Leistung Boni von (i) $ 18000, wenn das Unternehmen erfolgreich ist bzw. notiert an der New York Stock Exchange, der American Stock Exchange, der NASDAQ wählen, der NASDAQ Global Market oder den NASDAQ Capital Market, (ii) $ 8000, wenn das Unternehmen seinen EBT 2008 garantiert, und (iii) $ 20000, wenn das Unternehmen seinen EBT 2009 garantiert. Darüber hinaus, Frau Sung wird gewährt 300000 Optionen im Einklang mit der Unverfallbarkeit und Preisgestaltung festgelegten Zeitplan in den beschäftigungspolitischen Abkommens.
Die vorstehende Beschreibung der Beschäftigung Abkommens ist lediglich eine Zusammenfassung, erhebt keinen Anspruch auf Vollständigkeit und qualifiziert ist in seiner Gesamtheit durch einen Verweis auf den Volltext der Beschäftigung Abkommens. Die Beschäftigung Abkommens eingereicht wird als 10,1 Ausstellung zu diesem Formular 8-K, und der vollständige Wortlaut dieser Ausstellung ist hierin durch Bezugnahme.
Frau Sung hat keine familiären Beziehungen mit einem der leitenden Beamten oder Direktoren des Unternehmens. Es wurden keine Transaktionen in den vergangenen zwei Jahren, an denen die Gesellschaft oder einer ihrer Tochtergesellschaften wurde oder wird eine Partei, in der Herr Sung hatten oder haben wird, eine direkte oder indirekte materielle Interesse.
Date : 06/19/2008 @ 7:00AM
Source : PR Newswire
<< Back
[video] WallSt.net's '3 Minute Press Show' Features Executive Interviews and Highlights Recent Press for the Following: DAI, OPX
NEW YORK, June 19 /PRNewswire/ -- WallSt.net's 3-Minute Press Show is a daily video program hosted by WallSt.net reporter, Tracee Tolentino.
Shows air Monday through Friday on: http://tv.wallst.net/.
WallSt.net's 3-Minute Press Show features in-depth interviews with public company executives on their company and most recent press releases. The show is designed to provide viewers with insight into a company's most recent press release, and its impact on the company's growth.
The following executives were interviewed on today's show:
Han Tjan, Head of North American Corporate Communications for Daimler AG (NYSE:DAI) (http://www.daimler.com/). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/mktmaker/113/539
David McWilliams, President and CEO of Opexa Therapeutics, Inc. (NASDAQ:OPXA) (http://www.opexatherapeutics.com/). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/kazman/113/537
Declan Byrne, Chief Marketing Officer of Airspan Networks, Inc. (NASDAQ:AIRN) (http://www.airspan.com/). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/emceecooper/113/540
Chaim Levinson, Director of Investor Relations for BrainStorm Cell Therapeutics, Inc. (OTC:BCLI) (BULLETIN BOARD: BCLI) (http://www.brainstorm-cell.com/). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/aquaman/113/541
Elsa Sung, Chief Financial Officer of Genesis Pharmaceuticals Enterprises, Inc. (OTC:GTEC) (BULLETIN BOARD: GTEC) (http://www.genesis-china.net/). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/aquaman/113/542
Jeffrey Ross, Director of Finance for Newport Digital Technologies, Inc., a wholly-owned subsidiary of International Food Products Group, Inc. (OTC:IFDG) (BULLETIN BOARD: IFDG) (http://www.newportdt.com/). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/wsdave/113/538
About WallStreet Direct, Inc.
WallStreet Direct, Inc. a wholly-owned subsidiary of Financial Media Group, Inc. (OTC:FNGPOTC:-OTC:News) (BULLETIN BOARD: FNGP - News) , owns and operates WallSt.net (http://www.wallst.net/), a leading source of up-to-the-minute business news, comprehensive financial tools and original multimedia content for the investment community. In addition to WallSt.net, WallStreet Direct owns and operates WallStRadio (http://radio.wallst.net/) an online hub for business podcasts from well-known business news personalities and publishers, and WallStTV (http://tv.wallst.net/), a hub for business and finance video content. We have received four million restricted shares of IFDG from International Food Products Group, Inc. for media and advertising services. We have received two hundred eighty dollars from BrainStorm Cell Therapeutics, Inc. for press release dissemination services provided in 2007. To read our full disclaimer, and for a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.php.
Contact WallSt.net 800-4-WALLST
DATASOURCE: WallStreet Direct, Inc.; Opexa Therapeutics, Inc.; BrainStorm